Journey Medical has submitted a new drug application to the FDA for oral DFD-29 to treat rosacea. Two phase 3 clinical trials showed that DFD-29, minocycline hydrochloride modified release capsules, demonstrated safety and efficacy, with significant improvements in inflammatory lesions and erythema. The drug application is based on data from these trials, and the company is hopeful for FDA approval. Claude Maraoui, co-founder and CEO of Journey Medical, expressed excitement about the potential for DFD-29 to improve the treatment paradigm for rosacea patients. The drug is being developed in collaboration with Dr. Reddy’s Laboratories.
Source link
New drug application submitted for Journey Medical’s rosacea candidate
